Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Incanthera debuts

January 20, 2012 1:13 AM UTC

Newco Incanthera Ltd. (Merseyside, U.K.) raised L375,000 ($574,000) in a seed round led by the North West Fund for Biomedical, which is managed by SPARK Impact. The University of Bradford spinout is developing ICT2588 to treat solid tumors. The compound is an inactivated form of colchicine -- an inhibitor of microtubule polymerization. The compound is activated via cleavage of a protein tail by matrix metalloproteinases, which are found in high concentration in solid tumors. Clinical testing is expected to begin by 4Q12. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article